In the ALINA trial, ALECENSA showed a safety profile consistent with previous reports^1,2

No new or unexpected safety concerns were identified, including over a longer follow-up period of 4 years.^1,2

Similar numbers of AEs were observed between patients receiving ALECENSA vs. chemotherapy, despite treatment duration being 2 years with ALECENSA vs. 2 months with chemotherapy.²

The proportion of patients who discontinued treatment due to AEs was²:5.5% with ALECENSA vs. 12.5% with chemotherapy

ALINA: Adverse events occurring in ≥10% of patients in either trial group¹

Adverse event, n (%)^1,*  Safety evaluable cohort	ALECENSA (n=128)		Chemotherapy (n=120)
	Any Grade	Grade 3 or 4	Any Grade	Grade 3 or 4
Any adverse event	126 (98.4)	38 (29.7)	112 (93.3)	37 (30.08)
Nausea	10 (7.8)	0	87 (72.5)	5 (4.2)
Creatine kinase increased	55 (43.0)	8 (6.2)	1 (0.8)	1 (0.8)
Constipation	54 (42.2)	1 (0.8)	30 (25.0)	1 (0.8)
Aspartate aminotransferase increased	53 (41.4)	1 (0.8)	6 (5.0)	0
Alanine aminotransferase increased	43 (33.6)	2 (1.6)	11 (9.2)	0
Blood bilirubin increased	43 (33.6)	2 (1.6)	1 (0.8)	0
Decreased appetite	7 (5.5)	0	35 (29.2)	1 (0.8)
COVID-19	37 (28.9)	0	1 (0.8)	0
Myalgia	36 (28.1)	1 (0.8)	2 (1.7)	0
Anaemia	30 (23.4)	0	31 (25.8)	1 (0.8)
Vomiting	9 (7.0)	0	30 (25.0)	2 (1.7)
Alkaline phosphatase increased	32 (25.0)	0	4 (3.3)	0
White blood cell count decreased	2 (1.6)	0	23 (19.2)	4 (3.3)
Neutrophil count decreased	3 (2.3)	0	21 (17.5)	12 (10.0)
Asthenia	14 (10.9)	0	19 (15.8)	3 (2.5)
Neutropenia	2 (1.6)	0	19 (15.8)	10 (8.3)
Creatinine increased	19 (14.8)	1 (0.8)	6 (5.0)	0
Cough	19 (14.8)	1 (0.8)	4 (3.3)	0
Fatigue	18 (14.1)	1 (0.8)	16 (13.3)	2 (1.7)
Rash	18 (14.1)	1 (0.8)	7 (5.8)	0
Malaise	6 (4.7)	0	16 (13.3)	0
Weight increased	17 (13.3)	1 (0.8)	1 (0.8)	0
Diarrhoea	16 (12.5)	1 (0.8)	10 (8.3)	1 (0.8)
Headache	14 (10.9)	0	8 (6.7)	0
Dyspnoea	13 (10.2)	1 (0.8)	3 (2.5)	0
Dysgeusia	13 (10.2)	0	3 (2.5)	0
Oedema, peripheral	13 (10.2)	0	1 (0.8)	0

*Adverse event, n (%)1, Safety evaluable cohort**	ALECENSA (n=128)
	Any Grade	Grade 3 or 4
Any adverse event	126 (98.4)	38 (29.7)
Nausea	10 (7.8)	0
Creatine kinase increased	55 (43.0)	8 (6.2)
Constipation	54 (42.2)	1 (0.8)
Aspartate aminotransferase increased	53 (41.4)	1 (0.8)
Alanine aminotransferase increased	43 (33.6)	2 (1.6)
Blood bilirubin increased	43 (33.6)	2 (1.6)
Decreased appetite	7 (5.5)	0
COVID-19	37 (28.9)	0
Myalgia	36 (28.1)	1 (0.8)
Anaemia	30 (23.4)	0
Vomiting	9 (7.0)	0
Alkaline phosphatase increased	32 (25.0)	0
White blood cell count decreased	2 (1.6)	0
Neutrophil count decreased	3 (2.3)	0
Asthenia	14 (10.9)	0
Neutropenia	2 (1.6)	0
Creatinine increased	19 (14.8)	1 (0.8)
Cough	19 (14.8)	1 (0.8)
Fatigue	18 (14.1)	1 (0.8)
Rash	18 (14.1)	1 (0.8)
Malaise	6 (4.7)	0
Weight increased	17 (13.3)	1 (0.8)
Diarrhoea	16 (12.5)	1 (0.8)
Headache	14 (10.9)	0
Dyspnoea	13 (10.2)	1 (0.8)
Dysgeusia	13 (10.2)	0
Oedema, peripheral	13 (10.2)	0

*Adverse event, n (%)1, Safety evaluable cohort**	Chemotherapy (n=120)
	Any Grade	Grade 3 or 4
Any adverse event	112 (93.3)	37 (30.08)
Nausea	87 (72.5)	5 (4.2)
Creatine kinase increased	1 (0.8)	1 (0.8)
Constipation	30 (25.0)	1 (0.8)
Aspartate aminotransferase increased	6 (5.0)	0
Alanine aminotransferase increased	11 (9.2)	0
Blood bilirubin increased	1 (0.8)	0
Decreased appetite	35 (29.2)	1 (0.8)
COVID-19	1 (0.8)	0
Myalgia	2 (1.7)	0
Anaemia	31 (25.8)	1 (0.8)
Vomiting	30 (25.0)	2 (1.7)
Alkaline phosphatase increased	4 (3.3)	0
White blood cell count decreased	23 (19.2)	4 (3.3)
Neutrophil count decreased	21 (17.5)	12 (10.0)
Asthenia	19 (15.8)	3 (2.5)
Neutropenia	19 (15.8)	10 (8.3)
Creatinine increased	6 (5.0)	0
Cough	4 (3.3)	0
Fatigue	16 (13.3)	2 (1.7)
Rash	7 (5.8)	0
Malaise	16 (13.3)	0
Weight increased	1 (0.8)	0
Diarrhoea	10 (8.3)	1 (0.8)
Headache	8 (6.7)	0
Dyspnoea	3 (2.5)	0
Dysgeusia	3 (2.5)	0
Oedema, peripheral	1 (0.8)	0

**Preserving quality of life in ALK+ NSCLC³**

Sustainable tolerability enabling patients to benefit from longer treatment

Allows patients to live their lives with fewer treatment interruptions

Preserving HRQoL in early-stage ALK+ NSCLC^3*

Improvements in HRQoL were maintained in all domains, including measures of mental and physical well-being for
96 weeks³

With chemotherapy, HRQoL was low during treatment,
but did improve during the post-chemotherapy period.³

*Resected Stage IB-IIIA ALK NSCLC.³

AE, adverse event; ALK, anaplastic lymphoma kinase; HRQoL, health-related quality of life; NSCLC, non-small cell lung cancer.

1. Dziadziuszko R, et al. Updated results from the Phase III ALINA study of adjuvant alectinib vs chemotherapy in patients with early stage ALK+ non-small cell lung cancer (NSCLC). ESMO. 17–21 October 2025. Berlin, Germany. 2. Wu Y, et al. N Engl J Med 2024;390:1295–1276. 3. Nishio M, et al. Health-related quality of life (HRQoL) results for adjuvant alectinib vs chemotherapy in patients with resected ALK+ non-small cell lung cancer (NSCLC): Data from ALINA. ASCO. 31 May – 4 June 2024. Chicago, USA. Abstract: 8006.

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration, or usage in the country of your origin.

FOR HEALTHCARE PROFESSIONALS

Leaving website

In the ALINA trial, ALECENSA showed a safety profile consistent with previous reports^1,2

Similar numbers of AEs were observed between patients receiving ALECENSA vs. chemotherapy, despite treatment duration being 2 years with ALECENSA vs. 2 months with chemotherapy.²

**Preserving quality of life in ALK+ NSCLC³**

Sustainable tolerability enabling patients to benefit from longer treatment

Allows patients to live their lives with fewer treatment interruptions

Preserving HRQoL in early-stage ALK+ NSCLC^3*

Discover

Explore

FOR HEALTHCARE PROFESSIONALS

Leaving website

In the ALINA trial, ALECENSA showed a safety profile consistent with previous reports1,2

Similar numbers of AEs were observed between patients receiving ALECENSA vs. chemotherapy, despite treatment duration being 2 years with ALECENSA vs. 2 months with chemotherapy.2

Preserving quality of life in ALK+ NSCLC3

Sustainable tolerability enabling patients to benefit from longer treatment

Allows patients to live their lives with fewer treatment interruptions

Preserving HRQoL in early-stage ALK+ NSCLC3*

Discover

Explore

In the ALINA trial, ALECENSA showed a safety profile consistent with previous reports^1,2

Similar numbers of AEs were observed between patients receiving ALECENSA vs. chemotherapy, despite treatment duration being 2 years with ALECENSA vs. 2 months with chemotherapy.²

**Preserving quality of life in ALK+ NSCLC³**

Preserving HRQoL in early-stage ALK+ NSCLC^3*